• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BNO
Click for more information
5.26% 20.0¢

BIONOMICS LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
BNOBecoming a substantial holder19/12/11
BNOAppendix 3B16/12/11
BNOInvestor Presentation - December 201114/12/11
BNOAmended Change of Director's Interest Notice29/11/11
BNOAppendix 3B29/11/11
BNOChange of Director's Interest Notice29/11/11
BNOBNC210 Clinical Data Presented at Neuroscience 2011PRICE SENSITIVE15/11/11
BNOCEO Annual General Meeting Broadcast11/11/11
BNOAnnual General Meeting Results 201109/11/11
BNOCEO's AGM Presentation 201109/11/11
BNOChairman's AGM Presentation 201109/11/11
BNOAppendix 4C - quarterlyPRICE SENSITIVE28/10/11
BNOInvestor Presentation - ASX Small to Mid Caps25/10/11
BNONotice of Annual General Meeting/Proxy Form07/10/11
BNOBionomics Annual Report 201107/10/11
BNOOpen Briefing - CEO on BNC105 Update and Outlook05/10/11
BNOBNC105 Renal Cancer Trial UpdatePRICE SENSITIVE20/09/11
BNOLatest BNC210 Data Presented at Major Intl Conference01/09/11
BNOFull Year Statutory Accounts18/08/11
BNOBionomics' 2010/2011 Preliminary Final ResultsPRICE SENSITIVE18/08/11
BNOBNO CEO Broadcast - Clinical Trials Reach Key Milestones12/08/11
BNOBNO Investor Presentation - August 201103/08/11
BNOBNC105 Clinical Trials Reach Key MilestonesPRICE SENSITIVE03/08/11
BNOTrading HaltPRICE SENSITIVE01/08/11
BNOAppendix 4C - quarterlyPRICE SENSITIVE29/07/11
BNOChange of Director's Interest Notice05/07/11
BNOLapse of Options29/06/11
BNOPhase I BNC105 Clinical Trial PublishedPRICE SENSITIVE23/06/11
BNOMerck Serono Extends MS Collaboration with BionomicsPRICE SENSITIVE09/06/11
BNOChange of Director's Interest Notice03/06/11
BNOAppendix 3B03/06/11
BNOBNC105 Renal Cancer Trial To Be Presented AT ASCOPRICE SENSITIVE03/06/11
BNOAppendix 3B25/05/11
BNOOpen Briefing - Outlook and Strategic FocusPRICE SENSITIVE25/05/11
BNOBecoming a substantial holder20/05/11
BNOAppendix 3B19/05/11
BNOChange of Director's Interest Notice18/05/11
BNOCleansing Notice Under Section 708A of the Corporations Act18/05/11
BNOAppointment of Chief Financial Officer and Company Secretary16/05/11
BNOChange in substantial holding13/05/11
BNOSuccessful Register Repositioning CompletePRICE SENSITIVE13/05/11
BNOTrading HaltPRICE SENSITIVE12/05/11
BNOStart-up Australia Ventures Sells 60 Millions BNO SharesPRICE SENSITIVE12/05/11
BNOBNC210 - Further ValidationPRICE SENSITIVE10/05/11
BNOBionomics NOW May 2011 Newsletter06/05/11
BNOBNO Sells Thebarton Premises to Boost Cash ReservesPRICE SENSITIVE04/05/11
BNOAppendix 4C - quarterlyPRICE SENSITIVE29/04/11
BNOBionomics April Investor Presentation14/04/11
BNOResponse to ASX Price QueryPRICE SENSITIVE13/04/11
BNOAppendix 3B13/04/11
BNOBionomics Presents at Needham Healthcare Conference06/04/11
BNOBroadcast - CEO on Anit-Anxiety Drug Clinical Trials Results05/04/11
BNOBNC105 Data Presented at AACR Conference01/04/11
BNOInvitation to Tender for SharesPRICE SENSITIVE30/03/11
BNOAnti-Anxiety Drug Clinical Trials Successful ResultsPRICE SENSITIVE30/03/11
BNOTrading HaltPRICE SENSITIVE28/03/11
BNOChange in substantial holding09/03/11
BNOAppendix 3B23/02/11
BNOHalf Yearly Report and AccountsPRICE SENSITIVE11/02/11
BNOBionomics NOW February 2011 Newsletter10/02/11
BNOBNC105 Data Presented at Lorne Cancer Conference10/02/11
BNOPatent Applications Filed on Compounds to Treat Memory LossPRICE SENSITIVE04/02/11
BNOOpen Briefing - CEO on BNC Clinical Trials and Cash Position01/02/11
BNOAppendix 4C - quarterlyPRICE SENSITIVE31/01/11
BNOAppendix 3B19/01/11
BNOBionomics Biotech Showcase Presentation10/01/11
BNOCEO Update and US Investor Presentation10/01/11
BNOBionomics NOW December 2010 Newsletter17/12/10
BNODirectors' and Executive Management Share Trading Policy07/12/10
BNOBionomics Appoints Corporate Adviser26/11/10
BNOOpen Briefing - CEO on Company Update and BNC210 ResultsPRICE SENSITIVE25/11/10
BNOLatest BNC210 Data presented at US Neuroscience Conference15/11/10
BNOInvitation to Tender for the Purchase of Bionomics Shares11/11/10
BNOInvitation to tender for the purchase of 27.76% of sharesPRICE SENSITIVE10/11/10
BNOAppendix 3B10/11/10
BNOChange of Director's Interest Notice09/11/10
BNOAppendix 4C - quarterlyPRICE SENSITIVE27/10/10
BNOBionomics' CEO and Managing Director Extends Contract18/10/10
BNOAnnual General Meeting 2010 Results15/10/10
BNOCEO's Address to Shareholders15/10/10
BNOChairman's Address to Shareholders15/10/10
BNOBionomics Broadcast - CEO on Granted BNC210 European Trials11/10/10
BNOBNC210 - European Approval Granted for Two Phase Ib TrialsPRICE SENSITIVE05/10/10
BNOBionomics 2010 Annual Report and Notice of Meeting14/09/10
BNOOpen Briefing - BNO CEO on BNC210 Clinical TrialsPRICE SENSITIVE02/09/10
BNOBNC210 Data Presented at Leading European ForumPRICE SENSITIVE30/08/10
BNOFull Year Statutory AccountsPRICE SENSITIVE19/08/10
BNOFull Year Statutory Accounts19/08/10
BNOAppendix 4C - quarterly - corrected19/07/10
BNOAppendix 4C - quarterlyPRICE SENSITIVE19/07/10
BNOBionomics NOW - July Newsletter13/07/10
BNOLapse of Options06/07/10
BNOChange of Director's Interest Notice22/06/10
BNOBNC210 Phase I Trial SuccessfulPRICE SENSITIVE21/06/10
BNOBionomics Presents BNC105 Clinical Data at ASCOPRICE SENSITIVE07/06/10
BNOOpen Briefing - CEO on Merck Serono ExtensionPRICE SENSITIVE25/05/10
BNOMerck Serono Agreement ExtendedPRICE SENSITIVE24/05/10
BNOBionomics Limited Broadcast13/05/10
BNOAppendix 3B10/05/10
BNOSecond BNC210 Phase I Clinical Trial CommencesPRICE SENSITIVE06/05/10
BNOBecoming a substantial holder
19/12/11
BNOAppendix 3B
16/12/11
BNOInvestor Presentation - December 2011
14/12/11
BNOAmended Change of Director's Interest Notice
29/11/11
BNOAppendix 3B
29/11/11
BNOChange of Director's Interest Notice
29/11/11
BNOBNC210 Clinical Data Presented at Neuroscience 2011
15/11/11PRICE SENSITIVE
BNOCEO Annual General Meeting Broadcast
11/11/11
BNOAnnual General Meeting Results 2011
09/11/11
BNOCEO's AGM Presentation 2011
09/11/11
BNOChairman's AGM Presentation 2011
09/11/11
BNOAppendix 4C - quarterly
28/10/11PRICE SENSITIVE
BNOInvestor Presentation - ASX Small to Mid Caps
25/10/11
BNONotice of Annual General Meeting/Proxy Form
07/10/11
BNOBionomics Annual Report 2011
07/10/11
BNOOpen Briefing - CEO on BNC105 Update and Outlook
05/10/11
BNOBNC105 Renal Cancer Trial Update
20/09/11PRICE SENSITIVE
BNOLatest BNC210 Data Presented at Major Intl Conference
01/09/11
BNOFull Year Statutory Accounts
18/08/11
BNOBionomics' 2010/2011 Preliminary Final Results
18/08/11PRICE SENSITIVE
BNOBNO CEO Broadcast - Clinical Trials Reach Key Milestones
12/08/11
BNOBNO Investor Presentation - August 2011
03/08/11
BNOBNC105 Clinical Trials Reach Key Milestones
03/08/11PRICE SENSITIVE
BNOTrading Halt
01/08/11PRICE SENSITIVE
BNOAppendix 4C - quarterly
29/07/11PRICE SENSITIVE
BNOChange of Director's Interest Notice
05/07/11
BNOLapse of Options
29/06/11
BNOPhase I BNC105 Clinical Trial Published
23/06/11PRICE SENSITIVE
BNOMerck Serono Extends MS Collaboration with Bionomics
09/06/11PRICE SENSITIVE
BNOChange of Director's Interest Notice
03/06/11
BNOAppendix 3B
03/06/11
BNOBNC105 Renal Cancer Trial To Be Presented AT ASCO
03/06/11PRICE SENSITIVE
BNOAppendix 3B
25/05/11
BNOOpen Briefing - Outlook and Strategic Focus
25/05/11PRICE SENSITIVE
BNOBecoming a substantial holder
20/05/11
BNOAppendix 3B
19/05/11
BNOChange of Director's Interest Notice
18/05/11
BNOCleansing Notice Under Section 708A of the Corporations Act
18/05/11
BNOAppointment of Chief Financial Officer and Company Secretary
16/05/11
BNOChange in substantial holding
13/05/11
BNOSuccessful Register Repositioning Complete
13/05/11PRICE SENSITIVE
BNOTrading Halt
12/05/11PRICE SENSITIVE
BNOStart-up Australia Ventures Sells 60 Millions BNO Shares
12/05/11PRICE SENSITIVE
BNOBNC210 - Further Validation
10/05/11PRICE SENSITIVE
BNOBionomics NOW May 2011 Newsletter
06/05/11
BNOBNO Sells Thebarton Premises to Boost Cash Reserves
04/05/11PRICE SENSITIVE
BNOAppendix 4C - quarterly
29/04/11PRICE SENSITIVE
BNOBionomics April Investor Presentation
14/04/11
BNOResponse to ASX Price Query
13/04/11PRICE SENSITIVE
BNOAppendix 3B
13/04/11
BNOBionomics Presents at Needham Healthcare Conference
06/04/11
BNOBroadcast - CEO on Anit-Anxiety Drug Clinical Trials Results
05/04/11
BNOBNC105 Data Presented at AACR Conference
01/04/11
BNOInvitation to Tender for Shares
30/03/11PRICE SENSITIVE
BNOAnti-Anxiety Drug Clinical Trials Successful Results
30/03/11PRICE SENSITIVE
BNOTrading Halt
28/03/11PRICE SENSITIVE
BNOChange in substantial holding
09/03/11
BNOAppendix 3B
23/02/11
BNOHalf Yearly Report and Accounts
11/02/11PRICE SENSITIVE
BNOBionomics NOW February 2011 Newsletter
10/02/11
BNOBNC105 Data Presented at Lorne Cancer Conference
10/02/11
BNOPatent Applications Filed on Compounds to Treat Memory Loss
04/02/11PRICE SENSITIVE
BNOOpen Briefing - CEO on BNC Clinical Trials and Cash Position
01/02/11
BNOAppendix 4C - quarterly
31/01/11PRICE SENSITIVE
BNOAppendix 3B
19/01/11
BNOBionomics Biotech Showcase Presentation
10/01/11
BNOCEO Update and US Investor Presentation
10/01/11
BNOBionomics NOW December 2010 Newsletter
17/12/10
BNODirectors' and Executive Management Share Trading Policy
07/12/10
BNOBionomics Appoints Corporate Adviser
26/11/10
BNOOpen Briefing - CEO on Company Update and BNC210 Results
25/11/10PRICE SENSITIVE
BNOLatest BNC210 Data presented at US Neuroscience Conference
15/11/10
BNOInvitation to Tender for the Purchase of Bionomics Shares
11/11/10
BNOInvitation to tender for the purchase of 27.76% of shares
10/11/10PRICE SENSITIVE
BNOAppendix 3B
10/11/10
BNOChange of Director's Interest Notice
09/11/10
BNOAppendix 4C - quarterly
27/10/10PRICE SENSITIVE
BNOBionomics' CEO and Managing Director Extends Contract
18/10/10
BNOAnnual General Meeting 2010 Results
15/10/10
BNOCEO's Address to Shareholders
15/10/10
BNOChairman's Address to Shareholders
15/10/10
BNOBionomics Broadcast - CEO on Granted BNC210 European Trials
11/10/10
BNOBNC210 - European Approval Granted for Two Phase Ib Trials
05/10/10PRICE SENSITIVE
BNOBionomics 2010 Annual Report and Notice of Meeting
14/09/10
BNOOpen Briefing - BNO CEO on BNC210 Clinical Trials
02/09/10PRICE SENSITIVE
BNOBNC210 Data Presented at Leading European Forum
30/08/10PRICE SENSITIVE
BNOFull Year Statutory Accounts
19/08/10PRICE SENSITIVE
BNOFull Year Statutory Accounts
19/08/10
BNOAppendix 4C - quarterly - corrected
19/07/10
BNOAppendix 4C - quarterly
19/07/10PRICE SENSITIVE
BNOBionomics NOW - July Newsletter
13/07/10
BNOLapse of Options
06/07/10
BNOChange of Director's Interest Notice
22/06/10
BNOBNC210 Phase I Trial Successful
21/06/10PRICE SENSITIVE
BNOBionomics Presents BNC105 Clinical Data at ASCO
07/06/10PRICE SENSITIVE
BNOOpen Briefing - CEO on Merck Serono Extension
25/05/10PRICE SENSITIVE
BNOMerck Serono Agreement Extended
24/05/10PRICE SENSITIVE
BNOBionomics Limited Broadcast
13/05/10
BNOAppendix 3B
10/05/10
BNOSecond BNC210 Phase I Clinical Trial Commences
06/05/10PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL Welcome to the end of another week. Let's start with what HotCopper users have been watching and discussing.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.